Weber Barbara 4

What Happened

• Barbara Weber, Executive Chair and Director of Tango Therapeutics (TNGX), had automatic sell-to-cover transactions and received equity awards. On Feb 3, 2026 she sold 30,519 shares in two open-market transactions (30,186 shares at a weighted avg $12.26 for $369,999; 333 shares at $12.90 for $4,295), totaling about $374,294. On Feb 2, 2026 she was granted/issued 37,522 restricted stock units (RSUs) and a derivative equity award recorded as 222,132 shares (total grants = 259,654 shares) at $0.00 acquisition price.

Key Details

• Transaction dates/prices: Grants on 2026-02-02; sales on 2026-02-03. Sales weighted averages: $12.26 (range $11.88–$12.875) and $12.90 (range $12.88–$12.91).
• Shares sold: 30,519 shares for ~$374,294 (reported as sales, code S). Shares acquired: 37,522 RSUs (code A) and 222,132 derivative shares (code A, derivative).
• Vesting/conditions: RSUs vest in full on Feb 1, 2027 subject to continued service (footnote F1). The derivative award has an option-like vesting schedule: 12 equal monthly installments beginning after Jan 1, 2026 (footnote F5).
• Tax withholding: The sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vesting (footnote F2), not discretionary market sales by the insider.
• Filing timeliness: Report covers period 2026-02-02 and was filed 2026-02-04 — this appears to be a timely Form 4 filing.
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context

• Sales that are automatic to cover taxes (sell-to-cover) are routine and do not necessarily signal a change in insider sentiment. The awards (RSUs and derivative award) are subject to future vesting and service conditions; they are not immediately transferrable stock until vested.